Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P56178
UPID:
DLX5_HUMAN
Alternative names:
-
Alternative UPACC:
P56178; B7Z4P3; Q9UPL1
Background:
Homeobox protein DLX-5 plays a pivotal role in bone development, acting as a transcriptional factor. It is an immediate early BMP-responsive transcriptional activator crucial for osteoblast differentiation. Beyond promoting cell proliferation via MYC promoter activity up-regulation, DLX-5 serves as a positive regulator in both chondrogenesis and chondrocyte hypertrophy within the endochondral skeleton.
Therapeutic significance:
The involvement of Homeobox protein DLX-5 in Split-hand/foot malformation 1 with sensorineural hearing loss underscores its potential as a target for therapeutic intervention. Understanding the role of Homeobox protein DLX-5 could open doors to potential therapeutic strategies.